BR112014030060A2 - compostos de tetra-hidropirazolopirimidina - Google Patents

compostos de tetra-hidropirazolopirimidina

Info

Publication number
BR112014030060A2
BR112014030060A2 BR112014030060A BR112014030060A BR112014030060A2 BR 112014030060 A2 BR112014030060 A2 BR 112014030060A2 BR 112014030060 A BR112014030060 A BR 112014030060A BR 112014030060 A BR112014030060 A BR 112014030060A BR 112014030060 A2 BR112014030060 A2 BR 112014030060A2
Authority
BR
Brazil
Prior art keywords
tetrahydropyrazolopyrimidine
compounds
tetrahydropyrazolopyrimidine compounds
sle
antagonists
Prior art date
Application number
BR112014030060A
Other languages
English (en)
Other versions
BR112014030060B1 (pt
Inventor
Endo Atsushi
Carlson Eric
Hansen Hans
D Hawkins Lynn
Mackey Matthew
Boivin Roch
Ishizaka Sally
Schiller Shawn
Narayan Sridhar
Satoh Takashi
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112014030060A2 publication Critical patent/BR112014030060A2/pt
Publication of BR112014030060B1 publication Critical patent/BR112014030060B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo “compostos de tetra-hidropirazolopirimidina” as modalidades da presente descrição referem-se a compostos de tetra-hidropirazolopirimidina que atuam como antagonistas ou inibidores de receptores do tipo toll 7 e/ou 8, e a seu uso em composições farmacêuticas eficazes para o tratamento de lúpus eritematoso sistêmico (sle) e nefrite lúpica.
BR112014030060-7A 2012-05-31 2013-05-31 Compostos de tetra-hidropirazolopirimidina, composições farmacêuticas compreendendo ditos compostos, mistura racêmica e usos terapêuticos dos mesmos BR112014030060B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654023P 2012-05-31 2012-05-31
US61/654,023 2012-05-31
PCT/US2013/043679 WO2013181579A2 (en) 2012-05-31 2013-05-31 Tetrahydropyrazolopyrimidine compounds

Publications (2)

Publication Number Publication Date
BR112014030060A2 true BR112014030060A2 (pt) 2017-09-12
BR112014030060B1 BR112014030060B1 (pt) 2022-05-31

Family

ID=48626649

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014030060-7A BR112014030060B1 (pt) 2012-05-31 2013-05-31 Compostos de tetra-hidropirazolopirimidina, composições farmacêuticas compreendendo ditos compostos, mistura racêmica e usos terapêuticos dos mesmos

Country Status (34)

Country Link
US (5) US9126999B2 (pt)
EP (1) EP2855476B1 (pt)
JP (2) JP6285918B2 (pt)
KR (2) KR102403007B1 (pt)
CN (2) CN107344941B (pt)
AR (1) AR091236A1 (pt)
AU (2) AU2013267204B8 (pt)
BR (1) BR112014030060B1 (pt)
CA (1) CA2874445C (pt)
CL (1) CL2014003278A1 (pt)
CY (1) CY1122692T1 (pt)
DK (1) DK2855476T3 (pt)
ES (1) ES2709119T3 (pt)
HK (1) HK1203498A1 (pt)
HR (1) HRP20181889T1 (pt)
HU (1) HUE040562T2 (pt)
IL (2) IL268013B2 (pt)
JO (1) JO3407B1 (pt)
LT (1) LT2855476T (pt)
MX (1) MX368455B (pt)
MY (1) MY172926A (pt)
NZ (1) NZ703459A (pt)
PE (2) PE20190973A1 (pt)
PH (2) PH12014502660B1 (pt)
PL (1) PL2855476T3 (pt)
PT (1) PT2855476T (pt)
RS (1) RS57977B1 (pt)
RU (2) RU2733959C2 (pt)
SG (1) SG11201407890VA (pt)
SI (1) SI2855476T1 (pt)
TW (1) TWI572606B (pt)
UA (1) UA113440C2 (pt)
WO (1) WO2013181579A2 (pt)
ZA (1) ZA201409273B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
MY192489A (en) 2013-10-14 2022-08-23 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
BR112016008378B1 (pt) 2013-10-14 2022-11-08 Eisai R&D Management Co., Ltd Compostos de quinolina seletivamente substituídos ou sal dos mesmos, e composição farmacêutica contendo os ditos compostos
WO2015088045A1 (en) * 2013-12-13 2015-06-18 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
JP6527167B2 (ja) * 2014-03-27 2019-06-05 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＳ１阻害剤としての置換４，５，６，７−テトラヒドロ−ピラゾロ［１，５−ａ］ピリミジン誘導体および２，３−ジヒドロ−１Ｈ−イミダゾ［１，２−ｂ］ピラゾール誘導体
KR102531217B1 (ko) 2014-07-31 2023-05-10 바스프 에스이 피라졸의 제조 방법
US9938100B2 (en) 2014-12-30 2018-04-10 Kodak Alaris Inc. System and method for metallic object detection in a media transport system
ES2882543T3 (es) 2015-05-11 2021-12-02 Basf Se Proceso para la preparación de 4-amino-piridazinas
AU2015401326B2 (en) * 2015-07-03 2018-07-26 China Agricultural University Benzylhydrazone compounds and preparation method and application thereof
MX2018009453A (es) 2016-02-02 2018-09-21 Basf Se Proceso de hidrogenacion catalitico para preparar pirazoles.
CN107174585A (zh) * 2016-03-10 2017-09-19 兰州大学 可用作雄激素受体拮抗剂的吡啶并咪唑类化合物的新用途
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
WO2018026620A1 (en) * 2016-07-30 2018-02-08 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
WO2018024644A1 (en) * 2016-08-02 2018-02-08 Solvay Sa Manufacture of hydrazinyl compounds useful in the manufacture of pyrazole carboxylic acid and derivatives, hydrazinyl compounds and their use
US10660877B2 (en) 2016-09-09 2020-05-26 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
WO2018047081A1 (en) * 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
JP2020520379A (ja) 2017-05-18 2020-07-09 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． ヘテロアリール−ピラゾール誘導体ならびにその調製方法および医学的適用
WO2019028302A1 (en) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS
JP7266576B2 (ja) 2017-08-04 2023-04-28 ブリストル－マイヤーズ スクイブ カンパニー ［１，２，４］トリアゾロ［４，３－ａ］ピリジニル置換のインドール化合物
ES2945435T3 (es) 2017-11-14 2023-07-03 Bristol Myers Squibb Co Compuestos de indol sustituidos
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
EP3724183B1 (en) * 2017-12-15 2022-08-17 Bristol-Myers Squibb Company Substituted indole ether compounds
CN111819176B (zh) 2017-12-18 2023-12-15 百时美施贵宝公司 4-氮杂吲哚化合物
WO2019126082A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company 6-azaindole compounds
KR20200101402A (ko) 2017-12-19 2020-08-27 브리스톨-마이어스 스큅 컴퍼니 Tlr 억제제로서 유용한 치환된 인돌 화합물
US11420973B2 (en) * 2017-12-19 2022-08-23 Bristol-Myers Squibb Company Amide substituted indole compounds useful as TLR inhibitors
CN111491929B (zh) 2017-12-20 2023-11-28 百时美施贵宝公司 可用作tlr抑制剂的氨基吲哚化合物
EA202091479A1 (ru) 2017-12-20 2020-11-24 Бристол-Маерс Сквибб Компани Арил- и гетероарилзамещенные индольные соединения
EA202091530A1 (ru) 2017-12-20 2020-09-14 Бристол-Маерс Сквибб Компани Диазаиндольные соединения
CN111566093A (zh) * 2017-12-22 2020-08-21 索尔维公司 吡唑甲酸衍生物及其前体的制造方法
JP2021507889A (ja) 2017-12-22 2021-02-25 ノバルティス アーゲー ピラゾロピペリジン誘導体の新規な使用
US20210238136A1 (en) * 2018-06-07 2021-08-05 Daiichi Sankyo Company, Limited Azetidine derivative, and prodrug thereof
JP7367004B2 (ja) * 2018-09-06 2023-10-23 エフ． ホフマン－ラ ロシュ アーゲー 自己免疫疾患の処置のための新規のピラゾロビリジン化合物
EP3870589B1 (en) 2018-10-24 2023-09-06 Bristol-Myers Squibb Company Substituted indole dimer compounds
CN113039185A (zh) * 2018-11-09 2021-06-25 豪夫迈·罗氏有限公司 5-[6-[[3-(4,5,6,7-四氢吡唑并[4,3-c]吡啶-1-基)氮杂环丁烷-1-基]甲基]吗啉-4-基]喹啉-8-腈衍生物和类似化合物作为tlr7-9拮抗剂用于治疗系统性红斑狼疮
AU2020218383A1 (en) * 2019-02-07 2021-09-02 Beigene, Ltd. Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as TLR7 agonist
CN112321590A (zh) * 2019-08-02 2021-02-05 百济神州有限公司 咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物作为tlr8激动剂
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
EP4082611A4 (en) * 2019-12-06 2023-12-27 Daiichi Sankyo Company, Limited AZETIDINE SULPHONAMIDE COMPOUND
TW202302598A (zh) 2021-04-16 2023-01-16 美商基利科學股份有限公司 噻吩并吡咯化合物

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3116230B2 (ja) 1989-02-15 2000-12-11 武田薬品工業株式会社 三環式縮合ピリミジン誘導体
JPH04133055A (ja) 1990-09-25 1992-05-07 Konica Corp 色再現性の改良されたハロゲン化銀カラー写真感光材料
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
FR2733749B1 (fr) 1995-05-05 1997-06-13 Oreal Compositions pour la teinture des fibres keratiniques contenant des diamino pyrazoles, procede de teinture, nouveaux diamino pyrazoles et leur procede de preparation
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US6472416B1 (en) 1999-08-27 2002-10-29 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
RU2003120070A (ru) 2000-12-06 2004-12-27 Авентис Фармаа Дойчланд Гмбх (De) Производные гуанидина и амидина в качестве ингибиторов фактора ха
KR20030082982A (ko) 2001-03-14 2003-10-23 그뤼넨탈 게엠베하 치환된 피라졸로피리미딘 및 티아졸로피리미딘
CA2483075A1 (en) 2002-04-26 2003-11-06 Pfizer Products Inc. Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
DE10221100C1 (de) 2002-05-03 2003-06-05 Neuhaus Elektronik Gmbh Elektrisch leitfähige Dichtung sowie Verfahren und Vorrichtung zu deren Herstellung
JP2003327860A (ja) 2002-05-09 2003-11-19 Konica Minolta Holdings Inc 着色組成物、着色微粒子分散物、インクジェット用インク、インクジェット記録方法
DE60317684T4 (de) 2002-06-19 2011-06-22 Janssen Pharmaceutica N.V., 2340 SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
JP4133055B2 (ja) 2002-07-11 2008-08-13 株式会社イトーキ 移載機構を備えた自動倉庫
EP1572113B1 (en) 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
ZA200500782B (en) * 2002-08-26 2007-10-31 Takeda Pharmaceutical Calcium receptor modulating compound and use thereof
AU2003274652A1 (en) 2002-10-23 2004-05-13 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
EP1615667A2 (en) * 2003-04-11 2006-01-18 Novo Nordisk A/S Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
CA2524221A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
JP2006525366A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環式カルボン酸置換基
JP4580932B2 (ja) 2003-06-12 2010-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤のプロドラッグ
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
EP2236131A3 (en) 2003-07-01 2011-03-02 President and Fellows of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
FR2865208B1 (fr) 2004-01-16 2009-01-16 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
US7279232B2 (en) 2004-01-26 2007-10-09 Universal Display Corporation Electroluminescent stability
US20080004263A1 (en) 2004-03-04 2008-01-03 Santora Vincent J Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof
MXPA06012705A (es) 2004-05-04 2007-03-26 Acadia Pharm Inc Compuestos con actividad en receptor de estrogeno.
US7825265B2 (en) 2004-05-04 2010-11-02 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
AU2005295902A1 (en) 2004-10-12 2006-04-27 Decode Genetics Ehf Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
US20060122222A1 (en) 2004-11-18 2006-06-08 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
EP1829863A4 (en) 2004-11-26 2009-04-22 Takeda Pharmaceutical ARYLALCANOIC ACID DERIVATIVE
US20060276416A1 (en) 2005-01-20 2006-12-07 Sirtris Pharmaceuticals, Inc. Methods and compositions for treating flushing and drug induced weight gain
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006129587A1 (ja) 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. ピラゾロン誘導体を含有する医薬組成物
WO2006129583A1 (ja) 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. ピラゾロン誘導体
JP2008546643A (ja) 2005-06-06 2008-12-25 スミスクライン ビーチャム コーポレーション ４−置換アリールアミン誘導体および医薬組成物におけるその使用
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
KR20080049758A (ko) 2005-09-01 2008-06-04 아스텔라스세이야쿠 가부시키가이샤 통증 치료용으로 사용되는 피리다지논 유도체
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
WO2007087283A2 (en) 2006-01-23 2007-08-02 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
CA2645018A1 (en) 2006-03-08 2007-09-13 Takeda Pharmaceutical Company Limited Pharmaceutical combination
EP2013206A1 (en) 2006-04-25 2009-01-14 Astex Therapeutics Limited Pharmaceutical compounds
AU2007268056A1 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
EP2027116A2 (en) 2006-05-23 2009-02-25 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
AU2007257841A1 (en) 2006-06-09 2007-12-21 Icos Corporation Substituted phenyl acetic acids as DP-2 antagonists
US7989458B2 (en) 2006-07-14 2011-08-02 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
RU2450004C2 (ru) * 2006-08-04 2012-05-10 Мерц Фарма Гмбх Унд Ко. Кгаа Замещенные пиразолопиримидины, способ их получения и их применение в качестве лекарственного средства
WO2008033894A2 (en) 2006-09-14 2008-03-20 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
CA2669917A1 (en) 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines as chemokine receptor antagonists
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2008094992A2 (en) 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
EP2117311A4 (en) 2007-02-08 2011-05-11 Merck Sharp & Dohme THERAPEUTICS
EP2009002A1 (en) 2007-06-21 2008-12-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
US8022209B2 (en) 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
AU2007360955A1 (en) * 2007-11-15 2009-05-22 Eisai R & D Management Co., Ltd. Enantiomerically enriched imidazoazepinone compounds
AU2008335135A1 (en) * 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
US20120010177A1 (en) 2008-02-20 2012-01-12 The Wistar Institute / North Carolina State University MicroRNA Modulators and Method for Identifying And Using The Same
US8338392B2 (en) 2008-02-20 2012-12-25 The Wistar Institute MicroRNA modulators and method for identifying and using the same
EP2259680A4 (en) 2008-03-04 2012-01-25 Merck Sharp & Dohme SOLUBLE EPOXYHYDROLASE INHIBITORS, COMPOSITIONS COMPRISING SUCH COMPOUNDS AND TREATMENT METHODS THEREWITH
US9066951B2 (en) 2008-05-29 2015-06-30 Wisconsin Alumni Research Foundation Drugs to treat HPV infection
AU2009257748A1 (en) 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Imidazole derivatives useful as inhibitors of FAAH
CA2727242A1 (en) 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of faah
CA2724998A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
CA2725481A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
CN102076686B (zh) 2008-06-25 2013-03-06 百时美施贵宝公司 作为hiv附着抑制剂的二酮哌啶衍生物
CN102131810B (zh) 2008-06-25 2014-02-26 百时美施贵宝公司 作为抗hiv剂的二酮稠合的吡咯并哌啶类和吡咯并哌嗪类
US8263642B2 (en) 2008-06-25 2012-09-11 Vanderbilt University Antimicrobial compounds and methods of use thereof
TWI461423B (zh) 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
CN102123987A (zh) 2008-07-28 2011-07-13 吉里德科学公司 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
MX2011001313A (es) 2008-08-04 2011-03-04 Merck Sharp & Dohme Derivados de oxazol utiles como inhibidores de la amida hidrolasa de acidos grasos.
WO2010019392A1 (en) 2008-08-13 2010-02-18 Merck Sharp & Dohme Corp. Purine derivatives for treatment of alzheimer's disease
CA2733533C (en) 2008-08-25 2013-12-17 Irm Llc Hedgehog pathway modulators
US8853125B2 (en) 2008-09-24 2014-10-07 Basf Se Pyrazole compounds for controlling invertebrate pests
WO2010096115A1 (en) * 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
JP2012508250A (ja) 2008-11-07 2012-04-05 ワイス・エルエルシー キノキサリン系のｌｘｒモジュレーター
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
KR20110110183A (ko) 2009-01-19 2011-10-06 다이이찌 산쿄 가부시키가이샤 헤테로 원자를 갖는 고리형 화합물
ES2761295T3 (es) 2009-03-02 2020-05-19 Stemsynergy Therapeutics Inc Métodos y composiciones para su uso en el tratamiento del cáncer y para reducir los efectos mediados por Wnt en una célula
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2010141696A1 (en) 2009-06-04 2010-12-09 Dara Biosciences, Inc. Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
EP2470183B1 (en) 2009-08-26 2015-09-16 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
WO2011045415A2 (en) 2009-10-15 2011-04-21 Guerbet New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
AR078887A1 (es) 2009-11-06 2011-12-07 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen.
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
FR2953837B1 (fr) 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
EP2523561A4 (en) 2009-12-22 2013-06-05 Merck Sharp & Dohme 7,8-DIHYDRO-1H-IMIDAZO [2,1-B] PURIN-4 (5H) -ONE DERIVATIVES AND METHODS OF USE THEREOF
US8981084B2 (en) 2010-01-13 2015-03-17 Tempero Pharmaceuticals, Inc. Oxadiazole HDAC inhibitors
RU2012136624A (ru) 2010-01-28 2014-03-10 Мерк Шарп Энд Домэ Корп. Фармацевтические композиции для лечения боли и других показаний
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
EP2371219A1 (en) 2010-04-01 2011-10-05 Basf Se Herbicidal acylhydrazides
WO2011127070A2 (en) 2010-04-05 2011-10-13 Mannkind Corporation IRE-1α INHIBITORS
CA2794724A1 (en) 2010-04-22 2011-10-27 Merck Sharp & Dohme Corp. Oxazole derivatives useful as modulators of faah
JP2013525367A (ja) 2010-04-23 2013-06-20 キネタ・インコーポレイテツド 抗ウイルス性化合物
EP2401915A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
CN102048738A (zh) 2010-12-08 2011-05-11 辽宁利锋科技开发有限公司 含有环嘧耐平药用复合物的药物组合物制剂
JP6005740B2 (ja) 2011-07-29 2016-10-12 カリオファーム セラピューティクス，インコーポレイテッド ヒドラジド含有核輸送調節因子およびその使用
SG10201609097PA (en) 2011-07-29 2016-12-29 Karyopharm Therapeutics Inc Nuclear transport modulators and uses thereof
JP2013159564A (ja) * 2012-02-02 2013-08-19 Kowa Co ピラゾロピリミジン−７−アミン誘導体を有効成分とするｔｌｒ９阻害剤
AR089972A1 (es) 2012-02-13 2014-10-01 Bristol Myers Squibb Co Compuestos de enediino, conjugados de estos y sus usos y metodos
AR091194A1 (es) 2012-05-31 2015-01-21 Phenex Pharmaceuticals Ag TIAZOLES SUSTITUIDOS POR CARBOXAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين

Also Published As

Publication number Publication date
AR091236A1 (es) 2015-01-21
RU2733959C2 (ru) 2020-10-08
NZ703459A (en) 2016-09-30
UA113440C2 (xx) 2017-01-25
RU2677291C2 (ru) 2019-01-16
RU2014154397A (ru) 2016-07-27
PE20190973A1 (es) 2019-07-09
EP2855476A2 (en) 2015-04-08
CN104507939B (zh) 2017-07-25
US20160339032A1 (en) 2016-11-24
CN104507939A (zh) 2015-04-08
JP6619829B2 (ja) 2019-12-11
TWI572606B (zh) 2017-03-01
US9126999B2 (en) 2015-09-08
ZA201409273B (en) 2016-05-25
SI2855476T1 (sl) 2018-12-31
US20200347050A1 (en) 2020-11-05
AU2013267204B2 (en) 2017-04-06
MX2014014497A (es) 2015-06-02
PL2855476T3 (pl) 2019-02-28
CY1122692T1 (el) 2020-07-31
KR102403007B1 (ko) 2022-05-31
PE20150220A1 (es) 2015-02-14
AU2013267204A1 (en) 2015-01-29
US11130758B2 (en) 2021-09-28
US20180273532A1 (en) 2018-09-27
JP2018087221A (ja) 2018-06-07
LT2855476T (lt) 2019-01-10
PH12014502660A1 (en) 2015-01-21
EP2855476B1 (en) 2018-09-05
AU2013267204B8 (en) 2017-04-13
US20130324547A1 (en) 2013-12-05
US9446046B2 (en) 2016-09-20
JO3407B1 (ar) 2019-10-20
HRP20181889T1 (hr) 2019-01-11
CN107344941B (zh) 2020-04-21
JP6285918B2 (ja) 2018-02-28
TW201402575A (zh) 2014-01-16
MY172926A (en) 2019-12-14
US9850242B2 (en) 2017-12-26
AU2017204586B2 (en) 2018-11-08
HK1203498A1 (en) 2015-10-30
CA2874445C (en) 2022-06-21
BR112014030060B1 (pt) 2022-05-31
IL235986B (en) 2019-11-28
RU2018146532A (ru) 2019-01-31
WO2013181579A3 (en) 2014-03-27
KR20210076210A (ko) 2021-06-23
KR102268155B1 (ko) 2021-06-24
MX368455B (es) 2019-10-03
DK2855476T3 (en) 2018-12-17
US20160030430A1 (en) 2016-02-04
IL235986A0 (en) 2015-02-01
KR20150016366A (ko) 2015-02-11
IL268013B1 (en) 2024-01-01
WO2013181579A2 (en) 2013-12-05
US10640500B2 (en) 2020-05-05
IL268013A (en) 2019-09-26
PH12014502660B1 (en) 2015-01-21
IL268013B2 (en) 2024-05-01
PH12019500522A1 (en) 2020-11-04
RS57977B1 (sr) 2019-01-31
ES2709119T3 (es) 2019-04-15
JP2015523981A (ja) 2015-08-20
CL2014003278A1 (es) 2015-06-12
CA2874445A1 (en) 2013-12-05
CN107344941A (zh) 2017-11-14
HUE040562T2 (hu) 2019-03-28
AU2017204586A1 (en) 2017-07-27
SG11201407890VA (en) 2014-12-30
AU2013267204A8 (en) 2017-04-13
PT2855476T (pt) 2018-12-03
RU2018146532A3 (pt) 2019-06-21

Similar Documents

Publication Publication Date Title
BR112014030060A2 (pt) compostos de tetra-hidropirazolopirimidina
MX2019005192A (es) Compuestos de quinolina selectivamente sustituida.
MX363708B (es) Compuestos de quinolina selectivamente sustituidos.
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
BR112015022782A2 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
BR112015016395A2 (pt) pirazóis 3-substituídos e uso como inibidores de dlk
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
CL2014002915A1 (es) Compuestos derivados de imidazotiadiazol e imidazopirazina, como inhibidores del receptor activado de proteasa 4 (par4); composicion farmaceutica que los comprende; y su uso para inhibir o prevenir la agregacion plaquetaria y por lo tanto utiles en el tratamiento de un trastorno tromboembolico o para la profilaxis primaria o secundaria de un trastorno tromboembolico.
CL2014002096A1 (es) Compuestos heterocíclicos que comprenden un sistema enediino; conjugados de los mismos; composiciones que los comprenden; y uso para tratar el cáncer
CL2015000956A1 (es) Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros.
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
DOP2015000170A (es) Compuestos químicos
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
BR112015018047A2 (pt) composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
BR112015020222A8 (pt) composto de azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas
BR112016005589B8 (pt) Composição farmacêutica líquida, e, uso da mesma
BR112015030341A2 (pt) formulações de nanoparticulado e processo para prepará-las, composição farmacêutica e uso de composto ou seu sal farmaceuticamente aceitável e estabilizante de superfície
BR112015032161A2 (pt) método para prevenir e/ou tratar encefalopatia traumática crônica, composição farmacêutica e uso de antagonista do receptor da substância p
BR112013023337A2 (pt) hidrocloreto de ambroxol para tratamento de faringite aguda, uso do mesmo, composição aquosa borrifável e dispositivo borrifador para aplicação local

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/05/2013, OBSERVADAS AS CONDICOES LEGAIS